Rutledge SM, et al. - Researchers focused on the treatment of hepatitis C virus (HCV) infection in patients with mixed cryoglobulinemia syndrome (MCS) and cryoglobulinemic glomerulonephritis, especially on the use of direct-acting antiviral therapies. With good tolerability, direct-acting antiviral therapy enabled patients with HCV-MCS to achieve sustained virologic response in 297 out of 313 patients (95%). An excellent cure rate (94%) was also seen in patients with cryoglobulinemic glomerulonephritis. In patients treated with direct-acting antiviral therapies, no worsening of kidney function was reported. Immunosuppression was needed in less than 5% of patients with HCV-MCS treated with IFN-free direct-acting antiviral therapy. However, concomitant immunosuppression is still needed in patients with severe vasculitis.